Adenomyosis

1. Comprehensive Executive Overview

Adenomyosis (ICD-10: N80.0) is a common, benign, yet highly debilitating gynecological condition characterized by the ectopic presence of endometrial glands and stroma deep within the surrounding myometrium (the muscular wall of the uterus). This migration of endometrial tissue triggers reactive smooth muscle hyperplasia and hypertrophy, leading to diffuse or focal enlargement of the uterus.

Historically termed "endometriosis interna," adenomyosis is now recognized as a distinct clinical and pathological entity from pelvic endometriosis, though they frequently co-exist.

Under the International Federation of Gynecology and Obstetrics (FIGO) classification system for abnormal uterine bleeding (AUB), adenomyosis is categorized under the structural causes as AUB-A (within the PALM-COEIN framework).

Normal Uterus vs. Adenomyotic Uterus:
+----------------------------------+----------------------------------+
| Normal Uterus | Adenomyotic Uterus |
+----------------------------------+----------------------------------+
| - Clear Junctional Zone (JZ) | - Thickened/Disrupted JZ |
| - Symmetric Myometrium | - Asymmetric Myometrial Walls |
| - Normal Size and Shape | - Enlarged, Globular Uterus |
| - Regular Menstrual Shedding | - Ectopic Glands in Myometrium |
+----------------------------------+----------------------------------+

Epidemiology

• Prevalence: Historically thought to primarily affect multiparous women aged 40–50, modern high-resolution imaging (TVUS and MRI) reveals a high prevalence (up to 20–35%) among younger, nulliparous patients presenting with infertility or pelvic pain.
• Co-morbidities: Co-exists with uterine leiomyomas (fibroids) in approximately 35–50% of cases and with pelvic endometriosis in up to 70% of cases.

2. Detailed Pathophysiology, Etiology, and Risk Factors

Pathophysiology

The hallmark of adenomyosis is the disruption of the Endometrial-Myometrial Junctional Zone (EMJZ), a highly specialized, hormone-dependent inner layer of the myometrium.

Pathophysiological Cascade:
[Microtrauma to EMJZ] ---> [Tissue Injury and Repair (TIAR)] ---> [Local Hyperestrogenism]
|
[Myometrial Hypertrophy] <--- [Epithelial-Mesenchymal Transition] <-----+

Several key mechanisms drive the development and progression of adenomyosis:

1. Tissue Injury and Repair (TIAR) Hypothesis: Chronic microtrauma at the endometrial-myometrial interface—driven by hyperperistalsis (exaggerated uterine contractions)—triggers a local inflammatory response. This activates a healing cascade characterized by increased estrogen production, which further stimulates uterine contractions, creating a pathological feedback loop.
2. Epithelial-Mesenchymal Transition (EMT): Endometrial epithelial cells undergo phenotypic changes, acquiring mesenchymal characteristics (such as increased motility and invasiveness) that allow them to penetrate the disrupted EMJZ and invade the myometrium.
3. Local Hyperestrogenism and Progesterone Resistance: Adenomyotic tissue exhibits elevated expression of aromatase (the enzyme responsible for estrogen synthesis) and a downregulation of progesterone receptors (specifically PR-B). This local estrogen dominance promotes tissue proliferation, neuroangiogenesis, and survival of ectopic implants, while progesterone resistance impairs the normal secretory transformation of the endometrium.
4. Neuroangiogenesis and Inflammatory Mediators: Ectopic lesions secrete high levels of vascular endothelial growth factor (VEGF), nerve growth factor (NGF), cyclooxygenase-2 (COX-2), and inflammatory cytokines (IL-1β, TNF-α). This drives hypervascularity, sensory nerve fiber proliferation within the myometrium, and peripheral nerve sensitization, explaining the severe pain associated with the condition.

Etiology

While the exact etiology remains a subject of ongoing research, two primary theories exist:
* The Invagination Theory: The basal endometrium directly invaginates downward into the myometrium through a weakened or damaged EMJZ.
* The De Novo Metaplasia Theory: Ectopic endometrial tissue originates from pluripotent Müllerian stem cells residing within the myometrium that undergo metaplastic transformation.

Risk Factors

• Multiparity: Pregnancy and delivery-associated uterine stretching and placental separation may cause microtrauma to the EMJZ.
• Prior Uterine Surgery: Procedures such as Cesarean deliveries, dilation and curettage (D&C), hysteroscopic resections, and myomectomies disrupt the structural integrity of the EMJZ.
• Estrogen Exposure: Early menarche, short menstrual cycles, and obesity (increased peripheral conversion of estrone) elevate lifetime estrogen exposure.
• Tamoxifen Therapy: Used in breast cancer treatment, its partial estrogen-agonist effect on the uterus is associated with an increased risk of developing adenomyosis.

3. Signs, Symptoms, and Clinical Presentation

The clinical presentation of adenomyosis is highly variable; approximately one-third of affected individuals are completely asymptomatic. For symptomatic patients, the classic triad consists of severe dysmenorrhea, abnormal uterine bleeding (AUB), and a symmetrically enlarged, tender uterus.

                       ADENOMYOSIS SYMPTOMATOLOGY
                                   |
   +-------------------------------+-------------------------------+
   |                               |                               |

Pain Symptoms Bleeding Symptoms Structural Symptoms
- Severe Dysmenorrhea - Menorrhagia (Heavy Flow) - Globular Uterus
- Chronic Pelvic Pain - Prolonged Bleeding - Pelvic Fullness
- Deep Dyspareunia - Irregular Spotting - Bladder/Bowel Pressure

1. Abnormal Uterine Bleeding (AUB-A)

• Menorrhagia: Heavy, prolonged menstrual bleeding is the most common symptom (affecting up to 50% of patients). This is caused by the increased endometrial surface area of an enlarged uterus, compromised myometrial contractility (preventing effective vasoconstriction of spiral arteries), and elevated local prostaglandins.
• Metrorrhagia: Intermenstrual spotting or irregular bleeding.

2. Pelvic Pain

• Secondary Dysmenorrhea: Congestive, crampy menstrual pain that typically begins days before menses and worsens progressively. The pain is often refractory to standard over-the-counter analgesics.
• Chronic Pelvic Pain: Persistent, non-cyclical pelvic pain lasting more than six months.
• Deep Dyspareunia: Pain during sexual intercourse, stemming from a rigid, tender, and enlarged uterus.

3. Structural and Compressive Symptoms

• Globular Uterine Enlargement: The uterus may enlarge to the size of a 12-to-14-week gestation.
• Pelvic Pressure and Bloating: Patients frequently report a sensation of pelvic heaviness or a visible lower abdominal bulge.
• Urinary and Gastrointestinal Symptoms: Anterior uterine enlargement can compress the bladder, causing urinary frequency or urgency. Posterior enlargement can compress the rectosigmoid colon, leading to constipation and tenesmus.

4. Reproductive Impact

• Infertility: Adenomyosis alters endometrial receptivity by disrupting utero-tubal transport (due to abnormal peristalsis), impairing decidualization, and inducing high levels of local oxidative stress.
• Obstetric Complications: Increased risk of spontaneous abortion, preterm birth, preeclampsia, fetal growth restriction (FGR), and postpartum hemorrhage (PPH) due to impaired uterine contractility.

4. Standard Diagnostic Evaluation & Workup

Historically, adenomyosis was diagnosed exclusively via histopathological examination of a hysterectomy specimen. Today, advanced non-invasive imaging modalities allow for highly accurate clinical diagnosis.

Clinical Examination

On bimanual pelvic examination, the clinician typically finds a symmetrically enlarged ("globular") uterus that is soft, boggy, and diffusely tender, particularly during or immediately prior to menstruation. Mobility of the uterus is typically preserved unless co-existing pelvic endometriosis or adhesions are present.

Imaging Modalities

1. Transvaginal Ultrasound (TVUS) - The First-Line Modality

TVUS is the primary, cost-effective screening tool. The Morphological Uterus Sonographic Assessment (MUSA) group has standardized the ultrasound features of adenomyosis:

• Asymmetrical Myometrial Thickening: Typically involving the posterior wall.
• Myometrial Cysts: Anechoic, round spaces within the myometrium (representing hemorrhage within ectopic endometrial glands).
• Hypoechoic Linear Striations or Subendometrial Buds: Tiny projections extending from the endometrium into the inner myometrium.
• Fan-Shaped Shadowing: Acoustic shadowing originating from the endometrium-myometrium interface.
• Ill-defined Junctional Zone: Loss of a clear boundary between the endometrium and myometrium.
• Translesional Vascularity: On color Doppler, blood vessels cross the lesion perpendicularly rather than wrapping around it (distinguishing it from uterine fibroids).

2. Magnetic Resonance Imaging (MRI) - The Non-Invasive Gold Standard

MRI is indicated when TVUS is inconclusive, when planning conservative fertility-sparing surgery, or to differentiate adenomyosis from leiomyomas.

• T2-Weighted Sequences: The junctional zone appears as a low-signal-intensity band.
• Diagnostic Criteria:
  • Junctional Zone Thickness (JZmax) ≥ 12 mm: Highly predictive of adenomyosis.
  • JZmax < 8 mm: Effectively excludes the diagnosis.
  • JZmax between 8 and 12 mm: Equivocal; requires secondary signs (e.g., high-signal-intensity punctate foci on T2-weighted images representing hemorrhagic microcysts or dilated endometrial glands).
  • JZ Ratio (JZmax / Myometrial Thickness) > 40%: Strongly indicative of adenomyosis.

+--------------------------+-------------------------------------------------+
| Diagnostic Feature | MRI Presentation |
+--------------------------+-------------------------------------------------+
| Junctional Zone (JZ) | Thickened band ≥ 12 mm (T2-weighted images) |
| Ectopic Glands | High-signal intensity spots (T2-weighted) |
| Uterine Configuration | Diffuse globular shape or focal adenomyoma |
+--------------------------+-------------------------------------------------+

Lab Assays and Biopsy

• Serum CA-125: Often elevated in patients with severe adenomyosis, though it lacks specificity as it is also elevated in endometriosis, leiomyomas, and pelvic inflammatory disease. It is primarily used to monitor treatment response.
• Endometrial Biopsy / D&C: Generally not useful for diagnosing adenomyosis, as these procedures only sample the superficial endometrium, missing the deep myometrial lesions.
• Histopathological Gold Standard: Defined post-hysterectomy as the presence of endometrial glands and stroma situated more than one low-power field (typically > 2.5 mm) below the endometrial-myometrial junction.

5. Therapeutic Interventions

Management of adenomyosis must be highly individualized, guided by the patient’s age, symptom severity, desire for future fertility, and proximity to menopause.

                              TREATMENT ALGORITHM
                                       |
            +--------------------------+--------------------------+
            |                                                     |
    Fertility Desired                                   Fertility Complete
            |                                                     |

+------------+------------+ +------------+------------+
| | | |
Medical Therapy Conservative Surgery Medical Therapy Definitive Surgery
- NSAIDs - Adenomyomectomy - LNG-IUS (Mirena) - Hysterectomy
- COCs / Progestins - Transient GnRHa - GnRH Antagonists - UAE / HIFU

A. Pharmacotherapy

1. Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)

• Mechanism: Inhibit cyclooxygenase (COX) enzymes, reducing endometrial prostaglandin synthesis.
• Indications: First-line symptomatic relief for mild-to-moderate dysmenorrhea. Does not arrest disease progression.
• Regimen: Mefenamic acid (500 mg TID) or Ibuprofen (400–600 mg QID) initiated 24–48 hours prior to menses onset.

2. Hormonal Contraceptives

• Combined Oral Contraceptive Pills (COCs): Induce decidualization and subsequent atrophy of the endometrial tissue. Best prescribed as extended or continuous cycles to minimize withdrawal bleeding and associated pain.
• Progestin-Only Therapy: Oral progestins (e.g., Dienogest 2 mg daily) or depot medroxyprogesterone acetate (DMPA) injections suppress the hypothalamic-pituitary-ovarian axis, leading to anovulation and profound endometrial decidualization.

3. Levonorgestrel-Releasing Intrauterine System (LNG-IUS / Mirena)

• Mechanism: Delivers 20 mcg of levonorgestrel daily directly to the uterine cavity, inducing profound endometrial atrophy and downregulating local estrogen receptors.
• Efficacy: Considered the most effective medical treatment for adenomyosis. It significantly reduces menstrual blood loss, decreases uterine volume, and relieves dysmenorrhea.

4. Gonadotropin-Releasing Hormone (GnRH) Agonists and Antagonists

• Agents: GnRH Agonists (e.g., Leuprolide acetate depot 3.75 mg monthly) or GnRH Antagonists (e.g., Elagolix).
• Mechanism: Induce a state of profound hypoestrogenism ("pseudomenopause"), starving the estrogen-dependent adenomyotic lesions.
• Limitations: Long-term use (> 6 months) is limited by severe vasomotor symptoms, bone mineral density loss, and lipid profile alterations. "Add-back" therapy (low-dose estrogen/progestin) is required for extended regimens.

B. Surgical and Interventional Procedures

1. Uterine Artery Embolization (UAE)

• Mechanism: Minimally invasive angiographic procedure where embolic agents (e.g., polyvinyl alcohol particles) are injected bilaterally into the uterine arteries, cutting off the blood supply to the adenomyotic tissue, leading to ischemic necrosis.
• Efficacy: Highly effective for controlling menorrhagia and reducing uterine volume. Typically reserved for patients who have completed childbearing but wish to avoid a hysterectomy.

2. High-Intensity Focused Ultrasound (HIFU)

• Mechanism: An extracorporeal, non-invasive thermal ablation technique guided by ultrasound or MRI. Focused ultrasound waves generate localized thermal energy (> 65°C), causing coagulative necrosis of the adenomyotic lesions without damaging surrounding healthy myometrium.

3. Conservative Uterine-Sparing Surgery (Adenomyomectomy)

• Indication: Indicated for patients with focal adenomyosis (adenomyomas) who suffer from severe symptoms and wish to preserve fertility.
• Challenge: Unlike uterine fibroids, which have a distinct pseudocapsule and are easily enucleated, adenomyotic lesions interdigitate diffusely with healthy myometrium. Complete excision is challenging and carries a risk of uterine rupture in subsequent pregnancies.

4. Hysterectomy (Definitive Treatment)

• Indication: The only definitive cure for adenomyosis. Indicated for patients with severe, refractory symptoms who have completed childbearing.
• Approach: Can be total (removing the cervix) or subtotal (supracervical), performed laparoscopically, robotically, or vaginally. Ovarian preservation is highly recommended in premenopausal women, as adenomyosis is a uterine-confined disease.

C. Lifestyle and Complementary Management

• Anti-Inflammatory Diet: Diets rich in omega-3 fatty acids, antioxidants, and fiber can help mitigate systemic inflammation.
• Pelvic Floor Physical Therapy: Addresses secondary pelvic floor myofascial pain and hypertonicity caused by chronic pelvic pain.

6. Massive FAQ Section

Q1: What is the primary difference between adenomyosis and endometriosis?

While both conditions involve ectopic endometrial tissue, adenomyosis occurs when the endometrial glands and stroma invade the muscular wall of the uterus (the myometrium), causing a globally enlarged, boggy uterus. Endometriosis occurs when endometrial-like tissue implants outside the uterus, such as on the ovaries, fallopian tubes, peritoneum, or bowel. They are distinct diseases, though they frequently co-exist in the same patient.

Q2: Can adenomyosis cause infertility?

Yes. Adenomyosis can impair fertility through several mechanisms: it alters normal uterine peristalsis (disrupting sperm transport), induces chronic local inflammation and high oxidative stress in the uterine cavity (impairing embryo implantation), and causes progesterone resistance, which compromises endometrial receptivity.

Q3: Is adenomyosis a precursor to uterine cancer?

No. Adenomyosis is a benign gynecological condition. While it shares invasive-like characteristics (as endometrial glands invade the muscular layer), it is not a malignant or pre-malignant disease, and it does not increase a patient's risk of developing endometrial or ovarian cancer.

Q4: What is the non-invasive gold standard for diagnosing adenomyosis?

Magnetic Resonance Imaging (MRI) is the non-invasive gold standard. It is highly sensitive and specific, particularly because it can clearly visualize the Junctional Zone (JZ). A JZ thickness of 12 mm or greater is highly diagnostic of adenomyosis. Transvaginal Ultrasound (TVUS) remains the first-line screening tool due to its accessibility and lower cost.

Q5: Will my adenomyosis symptoms resolve after menopause?

Yes, in the vast majority of cases. Adenomyosis is an estrogen-dependent condition. Following menopause, estrogen levels drop significantly, causing the ectopic endometrial tissue within the myometrium to atrophy. Consequently, symptoms such as heavy menstrual bleeding and severe pelvic pain typically resolve, and the uterus shrinks in size.

Q6: What does it mean if my doctor says I have a "globular uterus"?

A "globular uterus" refers to a uterus that has lost its normal pear-like shape and has become symmetrically enlarged and rounded. This change in shape and size is caused by the diffuse infiltration of endometrial glands throughout the myometrium, which triggers reactive hypertrophy (growth) of the surrounding smooth muscle fibers.

Q7: Is a hysterectomy the only cure for adenomyosis?

Yes, a hysterectomy (removal of the uterus) is currently the only definitive cure for adenomyosis. However, it is not the only treatment option. Many patients successfully manage their symptoms through non-surgical means, such as the Levonorgestrel-releasing intrauterine system (LNG-IUS / Mirena), GnRH agonists/antagonists, or minimally invasive procedures like Uterine Artery Embolization (UAE).

Q8: Does adenomyosis cause weight gain or abdominal bloating?

Adenomyosis does not cause metabolic weight gain or fat accumulation. However, it can cause significant pelvic congestion and localized abdominal bloating. A severely enlarged, globular uterus can mimic a mid-pregnancy abdomen, causing a visible lower abdominal distension and pelvic fullness that patients often describe as "bloating."

Q9: How does the Mirena coil (LNG-IUS) help treat adenomyosis?

The Mirena coil (LNG-IUS) is highly effective because it releases a continuous, low dose of levonorgestrel (a progestin) directly into the uterine cavity. This local delivery induces profound atrophy of the endometrial lining and ectopic myometrial lesions, significantly reducing menstrual blood loss and alleviating severe dysmenorrhea.

Q10: Can adenomyosis be misdiagnosed as uterine fibroids?

Yes, misdiagnosis is common because both conditions cause uterine enlargement, heavy menstrual bleeding, and pelvic pain. However, on ultrasound or MRI, fibroids (leiomyomas) appear as well-circumscribed, encapsulated tumors that compress the surrounding tissue, whereas adenomyosis presents as diffuse, poorly demarcated thickening of the myometrium with tiny cystic spaces.

Related Clinical Integration

In the modern clinical management of adenomyosis, therapeutic strategies are tailored to the patient’s symptom severity and reproductive goals, often beginning with conservative interventions such as the Mirena / Copper T Intrauterine Device (IUD) / لولب ميرينا / لولب نحاسي (جهاز داخل الرحم) (أجهزة دعم وتكبير الجراحة) to effectively regulate hormonal cycles and alleviate heavy menstrual bleeding. For patients who do not achieve sufficient relief through medical management, minimally invasive options like Endometrial Ablation / استئصال بطانة الرحم (عملية صغرى في العيادة) may be considered, provided the depth of myometrial infiltration is limited. However, in cases of refractory symptoms or extensive disease progression where fertility preservation is no longer a priority, a Total Abdominal Hysterectomy (TAH) / استئصال الرحم الكلي عن طريق البطن (عملية كبرى في غرف العمليات) remains the definitive surgical standard to ensure the complete resolution of adenomyosis-related pathology.